Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1134153

USP

Cilostazol

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H27N5O2
Numéro CAS:
73963-72-1
Poids moléculaire :
369.46
Numéro MDL:
MFCD00866780
Code UNSPSC :
41116107
ID de substance PubChem :
329749401
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cilostazol

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

Clé InChI

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Informations sur le gène

human ... PDE3A(5139)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Application

Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1134164

Cilostazol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1134175

Cilostazol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1134186

Cilostazol Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1503

Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1653

Cilostazol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1676

Cilostazol Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2855

Cilostazol Related Compound A, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361d

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
Kelly C Rogers et al.
The Annals of pharmacotherapy, 46(6), 839-850 (2012-06-07)
To evaluate the addition of cilostazol to standard dual antiplatelet therapy (DAT) with aspirin and clopidogrel in patients receiving coronary stenting. Relevant information was identified through a search of MEDLINE (1966-November 2011), International Pharmaceutical Abstracts (1960-2011), and Cochrane Databases (publications
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid
Sayuri N Friedland et al.
The American journal of cardiology, 109(10), 1397-1404 (2012-03-03)
Cilostazol is a generic drug with antiplatelet and antiproliferative effects. It is unclear whether adding cilostazol to standard dual antiplatelet therapy (aspirin and clopidogrel) after percutaneous coronary intervention reduces restenosis and improves the outcomes. We, therefore, conducted a systematic review
Courtney J Warner et al.
Journal of vascular surgery, 59(6), 1607-1614 (2014-01-29)
Although cilostazol is commonly used as an adjunct after peripheral vascular interventions, its efficacy remains uncertain. We assessed the effect of cilostazol on outcomes after peripheral vascular interventions using meta-analytic techniques. We searched MEDLINE (1946-2012), Cochrane CENTRAL (1996-2012), and trial
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique